Cellectar Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cellectar Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.79M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($44.58M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($42.77M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($17.52M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($10.18M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($7.19M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($31.79M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($7.51M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($5.64M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($6.24M) | Oct 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.98M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($51.78M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($38.96M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($9.41M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($8.29M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($8.71M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($28.81M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($7.82M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($7.44M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($6.14M) | Oct 29, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.98M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $25.47M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $12.08M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $21.55M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $6.51M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $14.84M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $21.59M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $19.32M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $25.89M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $31.99M | Oct 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.06M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $9.80M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $25.85M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $30.35M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $13.52M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $12.09M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $12.05M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $7.17M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $6.60M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $7.48M | Oct 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.54M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.29M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($15.16M) | Mar 4, 2026 |
| FY2023 | Sep 30, 2023 | ($28.00M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($8.39M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $1.37M | Oct 29, 2024 |
| FY2024 | Dec 31, 2022 | $8.15M | Mar 13, 2025 |
| FY2023 | Sep 30, 2022 | $10.77M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $17.91M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $23.13M | Oct 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (36) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Oct 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (41) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Oct 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $23.29M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $9.56M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $18.99M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $5.15M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $12.68M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $19.87M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $17.79M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $24.81M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $30.63M | Oct 29, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $330.2K | Oct 20, 2016 |
| FY2014 | Dec 31, 2014 | $450.0K | May 20, 2015 |
| FY2013 | Dec 31, 2013 | $450.0K | Mar 19, 2014 |
| FY2012 | Dec 31, 2012 | $450.0K | Mar 28, 2013 |